ELAVL1 and triple-negative breast carcinoma: Furthermore, Niclosamide prevents the RNA-binding protein human antigen R (HuR; encoded by ELAV1) from stabilizing PD-L1 mRNA in triple-negative breast cancer, leading to decreased PD-L1 glycosylation and expression.